baird analyst on why he's skeptical about gilead's remdesivir clinical studies
Published 4 years ago • 9.1K plays • Length 3:20Download video MP4
Download video MP3
Similar videos
-
4:13
magnitude not there in terms of coronavirus gilead drug: baird senior analyst
-
5:01
why this raymond james analyst calls for a clinical reassessment of gilead's remedsivir treatment
-
2:21
coronavirus: 68% of patients showed improvement using gilead's remdesivir in 'compassionate use'
-
4:03
gilead ceo on promising study results for remdesivir covid-19 treatment
-
5:55
the outlook for therapeutics and vaccine stocks
-
3:48
a lot of focus on gilead has moved beyond covid-19: analyst
-
27:34
gilead's moving quickly with fda for approval of coronavirus drug remdesivir: ceo
-
17:43
dr. christine casey - june 23, 2021 update about unexplained bird illness
-
8:04
liesbeth ellinger on veterinary homeopathy research
-
4:48
gilead sciences ceo daniel o'day on the collaboration with biotech firm galapagos
-
0:26
daniel o’day of gilead sciences, inc. on covid-19 efforts
-
4:15
viread and hiv drug lawsuits against gilead sciences
-
0:41
what's good for insects is good for the birds
-
4:43
coronavirus tv episode 8: gilead’s expanded access
-
2:37
gilead's remdesivir treatment could see recurring revenue even if a covid-19 vaccine is found: jeffe
-
4:42
introduction standards for birds not bred for use in research under the animal welfare act
-
4:33
gilead's base business for hiv remains strong: biotech analyst
-
1:10
fearless for all
-
2:48
us allows emergency use of antiviral drug remdesivir to treat covid-19 patients
-
3:15
gilead drug more widely distributed in washington state than previously thought
-
0:52
baird’s core beliefs have led to the firm’s history of success
-
2:58
gilead sciences ceo on raising full-year guidance due to remdesivir sales